The family protecting HPH116 and related compounds, in Anti-allergic field, Anti-inflammatory field :

Method for inhibiting cytokine production by cells

Australian patent n° 13276/99 Canadian patent n° 2312023 European patent n° 98956724.3 Japanese patent n° 2000-522922 US patent n° 09/555258

Under H-Phar collaboration contract, Michel Goldman and colleagues at the Universite Libre of Brussels discovered that the drug also has immunosuppressive effects and may be useful in the treatment of transplant rejection, autoimmune diseases and allergic disorders. Goldman's team tested azodicarbonmide in mice carrying skin transplants and found that it delays the time to rejection of these allografts by inhibiting the proliferation of both CD4 T cells (helper cells) and CD8 T cells (killer cells), in addition to decreasing the release of cytokines from these immune cells.

Moreover analogue of Azodicarbonamide have been tested showing interesting results

Unpublished data